Attached files

file filename
EX-99.1 - PRESS RELEASE DATED MARCH 3, 2015 - QUANTRX BIOMEDICAL CORPex99-1.htm


   UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported):   March 3, 2015

Commission File Number:   000-17119

QuantRx Biomedical Corporation
(Exact name of small business issuer as specified in its charter)
 
  Nevada
(State or other jurisdiction of incorporation or organization)
330202574
(IRS Employer Identification No.)
 
10190 SW 90th Avenue, No. 4690, Tualatin, Oregon 97123
(Address of principal executive offices)
 
503-575-9385
(Registrant's Telephone number)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 



 
 
Item 8.01 Other Events.
 
On March 3, 2015, QuantRx Biomedical Corporation (the "Company") issued a press release providing an update on the technological progress of its genomic diagnostics platforms. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
 
Item 9.01 Financial Statements and Exhibits.
 
See Exhibit Index
 
 
 

 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
Date: March 4, 2015
QuantRx Biomedical Corporation
 
By:   /s/ Dr. Shalom Hirschman
 
        Name: Dr. Shalom Hirschman
        Title: Chief Executive Officer
 
 
 
 

 
 
Exhibit Index
 
 
  
 
Exhibit No.
 
 
Description
 
EX-99.1
  
Press Release dated March 3, 2015.